---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-22-000004"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:57:06.877143+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M

## Summary
- Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).
- Q4 total revenue $11.0M (+2% YoY); net loss $10.7M vs $4.6M loss in Q4 2020.
- FDA approved IDE for pivotal study in drug-resistant primary generalized epilepsy.
- 2022 guidance: full-year revenue $45-48M, initial implant revenue $39-42M.
- Cash and marketable securities $115.6M; long-term borrowings $49.8M as of Dec 31, 2021.

## SEC filing metadata
- accession: 0001528287-22-000004
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/0001528287-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/npce-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-22-000004
- JSON: https://secwatch.observer/filing/0001528287-22-000004.json
- Plain text: https://secwatch.observer/filing/0001528287-22-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.